SecProbe.io

June 28, 2013

Via E -mail
Martin P. Rosendale
Chief Executive Officer
Cytomedix, Inc.
209 Perry Parkway, Suite 7
Gaithersburg, MD 20877

Re: Cytomedix, Inc.
Post-effective amendment to Form S -3 on Form S -1
Filed June 25, 2013
 File No.  333-18370 3

Dear Mr. Rosendale:

We have limited our review of your registration statement to those issues we have
addressed in our comments.  In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the
requested information.   Where you do not believe o ur comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.

After reviewing any amendment to your registration statement and the information you
provide in response to these comme nts, we may have additional comments.

Selling Security Holders, page 17

1. Regarding your response to prior comment 1, we note that you mention that no
Cytomedix  affiliates sold securities registered for sale on this registration statement after
your notice.  However, it is unclear when you provided the notice.  Therefore, please tell
us directly whether any Cytomedix affiliates sold any securities registered for sale on t his
registration statement since March 17, 2013 .

Exhibit 5.1

2. The third paragraph of this exhibit appears to omit counsel ’s opinion on the shares
mentioned in clause (ii) of the exhibit ’s first paragraph .  Please file an opinion that
addresses all securities registered for sale on the registration s tatement.

Martin P. Rosendale
Cytomedix, Inc.
June 28, 2013
Page 2

 We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Securities Act of 1933 and
all applicable Securities Act rules require.   Since the company and its management are in
possession of all fact s relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made.

Notwithstanding our comments, before we can declare the amended registration
statement effective, the  company  should provide us with a letter, acknowledging that:

 should the Commission or the staff, acting pursuant to delegated authority, declare the
filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;

 the a ction of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the company from its full responsibility for
the adequacy and accuracy of the disclosure in the filing; and

 the company may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.

Please contact Tom Jo nes at (202) 551 -3602 or me at (202) 551 -3617 with any questions.

 Sincerely,

 /s/ Russell Mancuso

 Russell Mancuso
 Branch Chief

cc (via e -mail): F. Alec Orudjev, Esq.